Karen Robertson, APRN
Adult Health · Greenville, SCNPI 1447225610
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,416 of the $68,925 with a category attached, or 61.5%. 24 manufacturers reported payments, led by Akebia Therapeutics Inc at 38.7% of the total. Among adult health clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 632 payments — averaging $109.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$27K
- Amgen$21K
- AstraZeneca$12K
- Novartis$5K
- Otsuka America Pharmaceutical, Inc.$1K
- Bayer$610
- plus $3K from 18 others
What the payments were for
- Consulting fees$5,4258%
- Speaking & faculty fees$42,41662%
- Travel & lodging$7,85811%
- Food & beverage$12,82619%
- Education$4011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 122 | $26,701 |
| Amgen(2 entities) | 151 | $20,743 |
| AstraZeneca(2 entities) | 83 | $12,461 |
| Novartis | 26 | $4,734 |
| Otsuka America Pharmaceutical, Inc. | 101 | $1,013 |
| Bayer | 38 | $610 |
| Travere Therapeutics, Inc. | 19 | $571 |
| Mallinckrodt Hospital Products Inc. | 20 | $558 |
| ANI Pharmaceuticals, Inc. | 9 | $294 |
| Calliditas Therapeutics US Inc. | 11 | $244 |
| Vifor Pharma, Inc. | 13 | $241 |
| OPKO Pharmaceuticals, LLC | 7 | $145 |
| Boehringer Ingelheim | 6 | $128 |
| Fresenius USA Marketing, Inc. | 5 | $89 |
| Aurinia Pharma U.S., Inc. | 4 | $70 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| Apellis Pharmaceuticals, Inc. | 2 | $48 |
| Ardelyx, Inc. | 2 | $36 |
| GSK | 2 | $34 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Sanofi | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,925 in reported general payments places this provider in the 95th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $19,116 |
| FarxigaDapagliflozin Propanediol | 21 | $16,497 |
| Sevelamer Carbonate | 30 | $2,889 |
| Midodrine Hcl | 14 | $758 |
| Mycophenolate Mofetil | 15 | $709 |
| Torsemide | 31 | $554 |
| Lisinopril | 37 | $373 |
| Losartan Potassium | 31 | $329 |
| Amlodipine Besylate | 49 | $277 |
| Carvedilol | 22 | $249 |
| Furosemide | 59 | $208 |
| Allopurinol | 27 | $183 |
| Potassium Chloride | 11 | $182 |
| Doxazosin Mesylate | 23 | $176 |
| Metoprolol Succinate | 12 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $128 | $19,11613 claims |
| AstraZenecaFarxiga | $12,461 | $16,49721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 adult health providers in South Carolina.
Other adult health in Greenville
- Jessica RiceGreenville$15K
- Sheri MorrisGreenville$8K
- James McKenzieGreenville$8K
- Gary SzetoGreenville$6K
- John SharkeyGreenville$6K
- Sarah BaranskiGreenville$5K
- Brandi RuffoGreenville$4K
- Lynn CurryGreenville$4K
- Christine FranzeseTega Cay$30K
- Michelle PriceCharleston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.